🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  2. RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  3. RO7790118, RO7791094, RO7790118, Tiragolumab, Avastin 25 mg/ml concentrate for solution for infusion., RO7247669, Tecentriq 1 200 mg concentrate for solution for infusion, RO7790118, TPST-1120, ADG126, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  4. RO7881583, EMPAGLIFLOZIN, Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, SACITUZUMAB GOVITECAN , Verzenios 100 mg film-coated tablets, EMPAGLIFLOZIN, PALBOCICLIB, INAVOLISIB, Tecentriq 1 200 mg concentrate for solution for infusion, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, PALBOCICLIB, PALBOCICLIB, RoActemra 20 mg/mL concentrate for solution for infusion, Kisqali 200 mg film-coated tablets, Verzenios 50 mg film-coated tablets, Tecentriq, Abraxane 5 mg/ml powder for di

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  5. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  6. Rapamune 1 mg/mL oral solution, Rapamune 0.5 mg coated tablets, Co-Trimoxazole Forte 160/800mg Tablets, Rapamune 2 mg coated tablets, adeno-associated virus, serotype 9 (AAV9), PREDNISONE VIATRIS 5 mg, comprimé sécable, PREDNISONE VIATRIS 1 mg, comprimé, PREDNISONE VIATRIS 20 mg, comprimé sécable, Prednisone Olikla 2.5 mg tablety, Prednisone Olikla 10 mg tablety, Prednisone Olikla 50 mg tablety, Rapamune 1 mg coated tablets

    Alexion Europe SAS

    BAG3 Mutation Associated Dilated Cardiomyopathy

    phase 2 small molecule active

    1 trial

  7. Reblozyl 75 mg powder for solution for injection

    GlaxoSmithKline

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  8. Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

    Aldeyra Therapeutics

    Dry Eye

    phase 2 small molecule completed

    1 trial

  9. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  10. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndrome

    phase 2 small molecule completed

    1 trial

  11. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  12. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  13. Revefenacin Inhalation Solution [Yupelri]

    Theravance Biopharma Ireland Umited

    COPD

    phase 2 small molecule completed

    1 trial

  14. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  15. Revlimid 25 mg hard capsules, Isatuximab, Dexamethasone Tablets 2 mg, Revlimid 15 mg hard capsules, Isatuximab, VELCADE 1 mg powder for solution for injection, Revlimid 10 mg hard capsules

    Ningbo Cancer Hospital

    Newly diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  16. Revlimid 5 mg hard capsules, DEXAMETHASONE, DEXAMETHASONE , DARZALEX 1800 mg solution for injection, BORTEZOMIB , Revlimid 10 mg hard capsules, BORTEZOMIB, DEXAMETHASONE

    Pari Pharma GmbH

    PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATING DARATUMUMAB TO CHEMOTHERAPY AND STEM CELL TRANSPLANTATION

    phase 2 small molecule active

    1 trial

  17. Rifamycin SV sodium in situ gelling solution matching placebo (80 mL) for rectal administration, Rifamycin 1% in situ gelling solution (80 mL) for rectal administration

    Cosmo Technologies Ltd

    patients with mild to moderate left-sided ulcerative colitis

    phase 2 small molecule active

    1 trial

  18. Rixathon 100 mg concentrate for solution for infusion, Aplo-TCSE TCRaß+CD19+ depleto, Allogeneic peripheral blood-derived NK cells CD3- CD56+, Qarziba 4.5 mg/mL concentrate for solution for infusion, Melfalan Tillomed 50 mg polvere e solvente per soluzione iniettabile/infusione, TEPADINA 100 mg powder for concentrate for solution for infusion, Fludarabina Accord 25 mg/ml Concentrato per soluzione iniettabile o per infusione, Grafalon 20 mg/ml concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    Patient affected by high risk Neuroblastoma relapsed or in progression after first line treatment.

    phase 2 small molecule active

    1 trial

  19. RoActemra 162 mg solution for injection in pre-filled syringe., Humira 80 mg solution for injection in pre-filled pen

    Pari Pharma GmbH

    Severe uveitis of Behçet’s disease

    phase 2 small molecule active

    1 trial

  20. RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  21. RoActemra 20 mg/mL concentrate for solution for infusion, Glofitamab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  22. Rydapt 25 mg soft capsules, Dacogen 50 mg powder for concentrate for solution for infusion., Rydapt 25 mg soft capsules

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukemia, Myelodysplastic syndrome

    phase 2 small molecule active

    1 trial

  23. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  24. S230815 Solution for injection 10mg/ml

    The George Institute

    KCNT1-related Developmental and Epileptic Encephalopathy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources